Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges

Area of Science:

• Oncology
• Molecular Targeted Therapy
• Gastroenterology

Background:

• Biliary tract cancers (BTCs) encompass gallbladder cancer (GBC), ampulla of Vater cancer (AVC), intrahepatic cholangiocarcinoma (iCCA), and extrahepatic cholangiocarcinoma (eCCA).
• These are aggressive solid tumors with historically limited therapeutic strategies.
• Current treatment options for advanced or metastatic BTCs remain insufficient, with little improvement in prognosis over the past decade.

Purpose of the Study:

• To review recent clinical trial data on targeted therapies for BRAF-mutant BTCs.
• To highlight findings from the Phase II ROAR trial and discuss ongoing clinical trials.
• To explore the emerging role of BRAF inhibition in BTC management.

Main Methods:

• Review of recent clinical trials, including the Phase II ROAR trial.
• Focus on targeted therapies in BRAF-mutant populations.
• Analysis of ongoing and recruiting clinical trials for BTCs.

Main Results:

• Molecular profiling has advanced BTC management.
• Targeted therapies are currently approved only for intrahepatic cholangiocarcinoma (iCCA).
• BRAF inhibition is emerging as a potential treatment for BRAF-mutant BTCs.

Conclusions:

• Despite advances, the prognosis for metastatic BTCs has not significantly improved.
• BRAF mutations represent a targetable vulnerability in a subset of BTC patients.
• BRAF inhibitors offer a novel therapeutic avenue for patients with BRAF-mutant biliary tract cancers.